Nabi Biopharmaceuticals News
Most Popular Nabi Biopharmaceuticals Story
Nabi sells staph vax program to GSK for $46M
Nabi Biopharmaceuticals has struck a deal to sell off another big piece of itself. GlaxoSmithKline agreed to pay $46 million--$20 million upfront--for its PentaStaph program, a vaccine in development Read more...
Latest Headlines
- July 18, 2011
- November 16, 2009
- September 30, 2009
- August 7, 2009
- December 6, 2007
- November 9, 2007
- September 13, 2007
- September 11, 2007
- July 23, 2007
- July 18, 2007
- February 15, 2007
- August 16, 2006
- July 13, 2006
- June 13, 2006
- March 21, 2006
- March 14, 2006
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline
